ArticleJournal of diabetes investigation2026
Do the treatment selection factors emphasized in clinical guidelines-Chronic kidney disease, cardiovascular disease, and heart failure-contribute to the risk of urinary tract infections during the administration of sodium-glucose cotransporter-2 inhibitors?
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionSodium-glucose cotransporter-2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ-protective effects, leading to increased use in high-risk populations. However, whether urinary tract infection (UTI) risk associated with SGLT2Is differs according to the presence of these factors remains unclear. This study aimed to estimate UTI risk among SGLT2I users and treatment selection factors and examine whether these factors modify risk. We selected dipeptidyl peptidase-4 inhibitors (DPP4Is) as the comparators. MATERIALS AND
methodsThis retrospective cohort study used DeSC claims data from patients with diabetes mellitus who received their first prescription for either an SGLT2I or a DPP4I between October 2014 and February 2023. The analysis focused on data from 2019 to 2022. Hazard ratios (HRs) for UTI incidence were estimated using Cox proportional hazard regression.
resultsA total of 66,968 SGLT2I users and 170,678 DPP4I users were aged 65 years or older. UTI incidence among SGLT2I users was 2.04% in those with treatment selection factors and 0.84% in those without. Compared with DPP4I users, the HR for UTI was 0.80 in patients with treatment selection factors and 0.51 in those without treatment selection factors.
conclusionsSGLT2I use was not associated with an increase in UTI risk, regardless of treatment selection factor status. These findings suggest a favorable safety profile for SGLT2Is even among high-risk populations, supporting their use following clinical guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.